Roche and Alnylam Pharmaceuticals have entered into a major alliance in which Roche will obtain a non-exclusive license to Alnylam’s RNAi technology platform. The alliance will initially cover four therapeutic areas: oncology, respiratory diseases, metabolic diseases and certain liver diseases. The two companies will collaborate on RNAi drug discovery for one or more disease targets in these areas. Also, Roche will acquire Alnylam’s European research site in Kulmbach, Germany, which ...